Nuwellis Inc (OQ:NUWE)

Business Focus: Advanced Medical Equipment & Technology

Get the company report for the most recent outlook updated daily

May 02, 2024 09:00 am ET

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO)...

Apr 30, 2024 06:09 pm ET

Nuwellis Announces Closing of $2.7 Million Public Offering

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares...

Apr 30, 2024 04:41 pm ET

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis...

Apr 26, 2024 09:17 am ET

Nuwellis Announces Pricing of $2.7 Million Public Offering

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 11,250,000 shares of its common stock (or...

Apr 09, 2024 09:00 am ET

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow...

Mar 07, 2024 09:08 am ET

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its...

Mar 05, 2024 08:00 am ET

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: Record...

Feb 27, 2024 09:00 am ET

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5,...

Feb 22, 2024 07:58 am ET

Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received...

Feb 20, 2024 05:06 pm ET

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to two individuals entering into employment...

Feb 20, 2024 08:42 am ET

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned activities at the upcoming Technology and Heart Failure Therapeutics conference (THT 2024),...

Feb 06, 2024 09:00 am ET

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the publication of new data demonstrating the potential value of the Aquadex SmartFlow® system’s...

Jan 04, 2024 03:05 pm ET

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its specialty peripheral dual lumen...

Nov 28, 2023 08:00 am ET

New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on...

Nov 14, 2023 04:30 pm ET

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective November 14, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment...

Nov 07, 2023 08:00 am ET

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023....

Nov 01, 2023 08:00 am ET

Nuwellis Announces Board of Directors Transition

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November...

Oct 31, 2023 08:00 am ET

Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its strategic partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), received an...

Oct 18, 2023 04:15 pm ET

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company...

Oct 17, 2023 04:15 pm ET

Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 150,000 units (the...

Oct 13, 2023 08:30 am ET

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 150,000 units (the “Units”), with each Unit...

Oct 10, 2023 08:00 am ET

Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that its distribution partner, SeaStar Medical (SeaStar), received correspondence from the...

Sep 11, 2023 04:15 pm ET

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief...

Aug 08, 2023 08:15 am ET

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2023. Revenue of $2.1 million for the second...

Aug 08, 2023 08:00 am ET

Nuwellis Announces Plan for CFO Transition

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, announced today that Lynn Blake will be transitioning from her role as Chief Financial Officer to pursue broader career...

Jul 18, 2023 04:15 pm ET

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company...

Jun 20, 2023 08:30 am ET

Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has entered into a Supply and Collaboration Agreement with DaVita Inc. (NYSE: DVA) to pilot Aquadex...

Jun 13, 2023 04:15 pm ET

Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will...

Jun 05, 2023 04:15 pm ET

Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company’s Board of Directors. Mr. McCormick’s...

May 22, 2023 05:10 pm ET

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective May 19, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with...

May 09, 2023 08:00 am ET

Nuwellis, Inc. Announces First Quarter 2023 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023. Revenue of $1.8 million for the first quarter...

Apr 18, 2023 08:00 am ET

Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023. The company will...

Mar 21, 2023 08:00 am ET

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings...

Mar 01, 2023 08:00 am ET

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis, Inc. (Nasdaq: NUWE), today announced that, effective February 23, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to six individuals entering into employment...

Feb 28, 2023 08:00 am ET

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

Feb 23, 2023 04:15 pm ET

Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 23, 2023 08:00 am ET

Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI)

A recent editorial published in The Annals of Thoracic Surgery provides additional clinical evidence to support the role that ultrafiltration plays in preventing cardiac surgery-associated acute kidney injury (CSA-AKI), according to leaders at...

Feb 07, 2023 08:00 am ET

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28,...

Jan 09, 2023 08:00 am ET

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022....

Jan 05, 2023 02:40 pm ET

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO). In this new role,...

Jan 04, 2023 05:24 pm ET

Nuwellis, Inc. Announces Passage of Warrant Proposal

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m....

Dec 30, 2022 07:40 am ET

Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?

NEW YORK, Dec. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PALI, KALA, FSTX, NUWE, and TGTX.

Dec 29, 2022 01:34 pm ET

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)

SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) and Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis) announce an exclusive U.S. license and distribution agreement by Nuwellis of SeaStar Medical’s Selective Cytopheretic Device (SCD) for...

Dec 27, 2022 04:44 pm ET

Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that on December 27, 2022, the Company received formal notice from the Listing Qualifications Staff of The...

Dec 13, 2022 08:00 am ET

Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of the results from a 10-year, real-world retrospective analysis of 334...

Dec 08, 2022 09:49 am ET

Thinking about buying stock in My Size, GameStop, Nuwellis, Xpeng, or IQIYI?

NEW YORK, Dec. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYSZ, GME, NUWE, XPEV, and IQ.

Dec 08, 2022 08:10 am ET

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company’s Special Meeting of Stockholders, on December 7, 2022 at 2:00 p.m. (CST), was convened...

Nov 30, 2022 08:00 am ET

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set...

Nov 18, 2022 05:00 pm ET

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nuwellis, Inc. (Nasdaq: NUWE), today announced that, effective November 15, 2022, the independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to seven individuals entering into employment with the...

Nov 08, 2022 08:00 am ET

Nuwellis, Inc. Reports Third Quarter 2022 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022. Q3 Results and Recent Highlights:...

Nov 03, 2022 07:00 am ET

Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates

Nuwellis, Inc. (NasdaqCM: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the publication of promising clinical data supporting the use of kidney replacement therapy with...

Oct 19, 2022 04:15 pm ET

Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022

Nuwellis, Inc. (NASDAQ: NUWE) announced today that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Oct 19, 2022 07:00 am ET

Nuwellis Announces Appointment of Chief Financial Officer

Continuing its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE) today announced the appointment of Lynn Blake as Chief Financial...

Oct 18, 2022 04:15 pm ET

Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the closing of an underwritten public offering of units with gross proceeds of...

Oct 14, 2022 08:30 am ET

Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of...

Oct 03, 2022 07:00 am ET

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF clinical study analysis presented at the Heart Failure Society of America’s...

Sep 27, 2022 07:00 am ET

Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites for its pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in...

Aug 31, 2022 07:00 am ET

Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow® System...

Aug 25, 2022 07:00 am ET

U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology

Nuwellis, Inc. (Nasdaq: NUWE) a commercial stage company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it was awarded a patent from the United States Patent and Trademark Office for a novel...

Aug 19, 2022 03:00 pm ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective August 18, 2022, the independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to six individuals entering into employment with the...

Aug 19, 2022 08:00 am ET

Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022...

Aug 09, 2022 08:00 am ET

Nuwellis, Inc. Announces Second Quarter 2022 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights: Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the...

Jul 26, 2022 07:00 am ET

Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. (Nasdaq: NUWE) a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced the submission of the AVOID-HF clinical study analysis using the Finkelstein-Schoenfeld method of...

Jul 14, 2022 08:00 am ET

Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022

Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Jul 12, 2022 07:00 am ET

Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid...

Jun 29, 2022 07:00 am ET

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. REVERSE-HF will evaluate the clinical outcomes...

Jun 14, 2022 07:00 am ET

Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two new pediatric hospitals in Florida and...

May 17, 2022 04:25 pm ET

Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m., was convened and adjourned, without any business being conducted, due to lack of the required quorum. A...

May 10, 2022 08:00 am ET

Nuwellis, Inc. Announces First Quarter 2022 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights: Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the...

May 09, 2022 01:11 pm ET

Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting

Nuwellis, Inc. (Nasdaq: NUWE) today announced the presentation of three Aquadex-related abstracts at the annual Pediatric Academic Societies (PAS) meeting. This research was funded in part by unrestricted grants by Nuwellis to the University of...

Apr 12, 2022 08:00 am ET

Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022

Nuwellis, Inc. (NASDAQ: NUWE) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Mar 15, 2022 07:00 am ET

Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study

Nuwellis, Inc. (Nasdaq: NUWE) today announced it has received independent Institutional Review Board (IRB) approval for the trial protocol of the company’s REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study...

Mar 01, 2022 08:00 am ET

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following highlights: Generated $1.6 million in total revenue for the fourth quarter 2021, 19.6% below...

Feb 22, 2022 05:15 pm ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective February 22, 2022, the independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with the...

Feb 17, 2022 08:00 am ET

Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload

Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will evaluate the clinical outcomes and economic value of its Aquadex® therapy in comparison to intravenous diuretics for the treatment of fluid overload in patients with worsening heart...

Feb 01, 2022 08:00 am ET

Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022

Nuwellis, Inc. (NASDAQ: NUWE) announced today that its fourth quarter 2022 financial results will be released on Tuesday, March 1, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Jan 25, 2022 08:00 am ET

New Category III CPT Code for the Nuwellis Aquadex Ultrafiltration System is Now in Effect

Nuwellis, Inc. (Nasdaq: NUWE) today announced that the new and dedicated Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration, is now in effect. Healthcare providers can utilize this code when using...

Nov 19, 2021 04:00 pm ET

Nuwellis, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective November 17, 2021, the independent directors approved an equity award under Nuwellis’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the...

Nov 09, 2021 08:00 am ET

Nuwellis, Inc. Announces Third Quarter 2021 Financial Results

Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights: Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year...

Nov 04, 2021 08:00 am ET

Aquadex SmartFlow® System by Nuwellis Selected as a 2021 R&D 100 Awards Winner

Nuwellis, Inc. (NASDAQ: NUWE) was honored at the 2021 R&D 100 Awards last month, with its Aquadex SmartFlow® system selected as a winner in the Analytical/Test category. The awards, presented by R&D World, recognize commercial products,...

Oct 19, 2021 08:00 am ET

Nuwellis Selected as a Recipient of the Governor’s International Trade Award

Nuwellis, Inc. (NASDAQ: NUWE) was honored last week with the 2021 Governor's International Trade Award by Minnesota Governor Tim Walz. This award honors Minnesota companies that are developing and continuing to grow a significant part of their...

Oct 14, 2021 04:03 pm ET

Nuwellis, Inc. To Announce Third Quarter 2021 Financial Results on November 9, 2021

Nuwellis, Inc. (NASDAQ: NUWE), announced today that its third quarter 2021 financial results will be released on Tuesday, November 9, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Sep 21, 2021 08:00 am ET

Nuwellis Receives CE Mark for 24-Hour Blood Circuit Set

Nuwellis, Inc. (NASDAQ: NUWE), a company focused on providing solutions for patients suffering from fluid overload, today announced that it has received CE Mark Certification for its 24-Hour Blood Circuit Set (UF 500-24 Hour). The UF 500-24 Hour...

Sep 17, 2021 04:00 pm ET

Nuwellis, Inc. Announces Closing of $10.0 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the closing of its previously announced underwritten public offering of 4,005,588 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of...

Sep 15, 2021 08:18 am ET

Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock

Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the pricing of an underwritten public offering of 3,483,120 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of approximately $8.7 million prior...

Sep 14, 2021 04:03 pm ET

Nuwellis, Inc. Announces Proposed Underwritten Public Offering of Common Stock

Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by the Company. The...

Sep 14, 2021 08:00 am ET

Nuwellis, Inc. Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective September 13, 2021, the independent directors approved an equity award under Nuwellis’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the...

Aug 31, 2021 07:00 am ET

Nuwellis Inc. to Speak at Upcoming Investor Conferences

Nuwellis, Inc. (NASDAQ: NUWE), a company focused on providing solutions for patients suffering from fluid overload, announced today that Nestor Jaramillo Jr., Chief Executive officer, and George Montague, Chief Financial Officer, are scheduled to...

Aug 24, 2021 09:00 am ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective August 18, 2021, the independent directors approved four equity awards under Nuwellis’ 2021 Inducement Plan, as material inducement to four individuals entering into employment with the...

Aug 10, 2021 08:00 am ET

Nuwellis, Inc. Announces 35 Percent Increase in Revenue for Second Quarter 2021 Over Previous Year and Provides Company Update

Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2021, which included the following highlights: Reported record quarterly revenue of $2.5 million, a 35 percent increase compared to the prior year...

Aug 05, 2021 08:00 am ET

Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant

Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (Nasdaq: NUWE) plans to fill this unmet need with the development of a fully...

Jul 27, 2021 04:03 pm ET

Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

Nuwellis, Inc. (NASDAQ: NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the...

Jul 13, 2021 08:00 am ET

American Medical Association Issues New CPT Code for Nuwellis’ Aquadex Ultrafiltration

In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for...

Jul 06, 2021 04:03 pm ET

Nuwellis Inc. to Participate at the 2021 Ladenburg Thalmann Healthcare Conference

Nuwellis, Inc. (NASDAQ: NUWE), a company focused on providing solutions for patients suffering from fluid overload, today announced that, Nestor Jaramillo, Chief Executive officer, and George Montague, Chief Financial Officer, are scheduled to...

Jul 01, 2021 04:00 pm ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective June 30, 2021, the Compensation Committee of the Board of Directors approved an equity award to George Montague under Nuwellis’ 2021 Inducement Plan, as a material inducement to Mr....

Jun 24, 2021 08:00 am ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective June 22, 2021, the independent directors approved four equity awards under Nuwellis’ 2021 Inducement Plan, as material inducement to four individuals entering into employment with the...

Jun 22, 2021 08:00 am ET

Nuwellis Announces New Appointments to Leadership Team

Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc.,...

Jun 01, 2021 08:00 am ET

Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration

Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc., has been awarded a three-year national contract with Premier, Inc., effective today. The new Aquapheresis category agreement allows Premier members, at their discretion, to take advantage...

May 20, 2021 04:03 pm ET

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective May 19, 2021, the independent directors approved eight equity awards under Nuwellis’ 2021 Inducement Plan, as material inducement to an individual entering into employment with the...

May 17, 2021 08:00 am ET

ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure

Data supporting the effectiveness of Aquadex FlexFlow® system in the treatment of acutely decompensated heart failure (ADHF) patients was presented May 16th at the 2021 American College of Cardiology conference (ACC). The single-center study...

May 13, 2021 08:45 am ET

Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology

Reaffirming its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc., today announced that its Aquadex...

May 11, 2021 08:00 am ET

Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update

Nuwellis, Inc. (Nasdaq: NUWE) (previously CHF Solutions, Inc.) announced today its results for the first quarter ended March 31, 2021, which included the following highlights: Completed corporate rebranding from CHF...

Apr 29, 2021 04:05 pm ET

Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021

Nuwellis, Inc. (NASDAQ:NUWE), formally CHF Solutions, announces today that its first quarter 2021 financial results will be released on Tuesday, May 11, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which...

Apr 27, 2021 09:00 am ET

CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis

Company names are reflective of the services provided to its customers, and CHF Solutions – a leader and pioneer in the heart failure space – has evolved to serve more than just the chronic heart failure community. The company today announced it is...

Ad blocking detected

Nuwellis Inc (OQ:NUWE)

Business Focus: Advanced Medical Equipment & Technology